New Once-Daily painkiller could reduce opioid use after surgery

NCT ID NCT06423703

Completed Symptom relief Sponsor: Tris Pharma, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 3 trial tested a new drug called cebranopadol (TRN-228) for moderate to severe acute pain after bunionectomy. 240 participants received either cebranopadol once daily, oxycodone four times daily, or placebo for three days. The study measured pain relief and whether patients needed extra opioid rescue medication.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cebranopadol (also called TRN-228)
What this could lead to: If successful, cebranopadol could provide a new once-daily option for managing acute pain after surgery, potentially reducing the need for opioid rescue medication.
What could go wrong: This is a completed Phase 3 trial, but results are not yet published. The drug may not prove significantly better than placebo or existing treatments, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE PAIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Acute Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE PAIN

Contacts and locations

Locations

ALLEVIATE 2 Site 001101

Salt Lake City, Utah, 84107, United States
ALLEVIATE 2 Site 001102

Atlanta, Georgia, 30331, United States
ALLEVIATE 2 Site 001103

Tampa, Florida, 33613, United States
ALLEVIATE 2 Site 001104

McAllen, Texas, 78501, United States
ALLEVIATE 2 Site 001105

Pasadena, Maryland, 21122, United States
ALLEVIATE 2 Site 001106

Little Rock, Arkansas, 72211, United States
ALLEVIATE 2 Site 001107

Overland Park, Kansas, 66212, United States
ALLEVIATE 2 Site 001108

Sheffield, Alabama, 35660, United States
ALLEVIATE 2 Site 001111

San Antonio, Texas, 78240, United States
Alleviate 2 001113

Houston, Texas, 77043, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.